Bruce E. Sands
Member of Clinical Advisory BoardDr. Bruce E. Sands, M. D. M. S, is Member of Scientific & Clinical Advisory Board of Equillium, Inc. from 2025. Dr. Sands is Member of Clinical Advisory Board of Caldera Therapeutics, Inc. He is Member of Inflammatory Bowel Disease Clinical Advisory Board at AltruBio Inc. since February 2026. He serves as Member of IBD Scientific Advisory Board at Thetis Pharmaceuticals LLC. Dr. Sands serves as Member of Clinical Advisory Board of Palisade Bio, Inc since February 2024. He serves as Member of Clinical Advisory Board at Morphic Holding, Inc. Dr. Sands is Member of Scientific Advisory Board of Ventyx Biosciences, Inc. He was Member of Clinical and Scientific Advisory Board at Ventyx Biosciences, Inc. Dr. Sands serves as a Member of Advisory Board North America at InDex Pharmaceuticals Holding AB (publ). He serves as a Member of Scientific Advisory Board at Artizan Biosciences, Inc. since May 2022. He serves as Member of Inflammatory Bowel Disease Clinical Advisory Board at Biora Therapeutics, Inc. (formerly known as Progenity, Inc.) since June 2021 and also serves as its Chairman of Inflammatory Bowel Disease Clinical Advisory Board since September 2022. He serves as Business & Scientific Advisor of Avaxia Biologics, Inc. Dr. Sands is Chief of the Henry D. Janowitz Division of Gastroenterology at the Mount Sinai School of Medicine in NY since 2010. He was Member of Scientific Medical Advisory Board at Immunic, Inc since November 2020 until August 2026. Dr. Sands serves as the Chairman of Scientific Advisory Board at Prometheus Biosciences, Inc. since May 2022 and as its had served as the Member of its Scientific Advisory Board until May, 2022. Dr. Sands is the Dr. Burrill B. Crohn Professor of Medicine at the Icahn School of Medicine at Mount Sinai, New York. He also served as the hospital's Acting Chief of the Gastrointestinal Unit as well as Associate Professor of Medicine at Harvard Medical School. He has served as the Chair of the Clinical Research Alliance of the Crohn's Foundation of America, Chair of the Immunology, Microbiology and Inflammatory Bowel Disease Section of the American Gastroenterological Association (AGA) and Chair of the International Organization for the Study of IBD. He was an Associate Professor of Medicine at HMSl, Associate Physician at Massachusetts General Hospital, Medical Co Director of the MGH Crohn's and Colitis Center. Dr. Sands is an American Gastroenterological Association Fellow and a Fellow of the American College of Gastroenterology. He is also Chair of the Clinical Research Alliance of the Crohn's & Colitis Foundation of America, a national clinical research network and serves on the CCFA's National Scientific Advisory Committee. Dr. Sands serves as Member of the Scientific Advisory Board at Cequent Pharmaceuticals, Inc. Dr. Sands serves as an associate editor and Member of the editorial Board for Inflammatory Bowel Diseases. He has published many peer reviewed articles, abstracts and textbook chapters on the etiology, diagnosis, prognosis and treatment of IBD. His postgraduate training included an internship and residency in internal medicine at the Hospital of the University of Pennsylvania. He also completed clinical and research fellowships at MGH. In addition, Dr. Sands was awarded a Master of Science degree in Epidemiology at the Harvard School of Public Health in 2001. Dr. Sands received MD from Boston University School of Medicine in 1987 and completed a residency in internal medicine at the Hospital of the University of Pennsylvania in Philadelphia. Dr. Sands was awarded his BA from Boston University. He completed his clinical and research fellowships at the Massachusetts General Hospital. Dr. Sands also holds a Master of Science in epidemiology from Harvard School of Public Health. He was the lead investigator of the landmark studies ACCENT 2, UNIFI and VARSITY, published in the New England Journal of Medicine.
Positions
- Company NamePalisade Bio, Inc.Stock CodePALIPositionMember of Clinical Advisory BoardColleagues
- JDJ. D. FinleyCEO, CFO & Director
- DADonald A. WilliamsIndependent Chairman of the Board
- MLMitchell Lawrence JonesPresident & Chief Medical Officer
- RCRamesh C. DonthamsettyHead of IR and Corporate Strategy
- JEJulien E. CapersGeneral Counsel & Corporate Secretary
- JHJoerg HeyerHead of Translational Science & Medicine
- ECEmil ChuangIndependent Director
- BWBinxian WeiIndependent Director
- Company NameBiora Therapeutics, Inc.Stock CodeBIORQPositionChairman of Inflammatory Bowel Disease Clinical Advisory BoardColleagues
- APAditya P. MohantyCEO & Director
- JDJeffrey Donald AlterIndependent Chairman
- CNClarke NeumannSenior VP, General Counsel & Secretary
- KHKevin HoweSenior VP of Strategic Operations
- PSPaul ShabramHead of Technical Operations
- JKJames KnightHead of Business Development
- BLBrian L. KotzinIndependent Director
- BEBruce E. SandsChairman of Inflammatory Bowel Disease Clinical Advisory Board
- JAJill Ann HoweIndependent Director
